Polysubstance use in the U.S. opioid crisis.

Polysubstance use in the U.S. opioid crisis.
复制标题

DOI:
10.1038/s41380-020-00949-3
复制
发表时间:
2021-01
影响因子:
11
通讯作者:
DuPont RL
DuPont RL
中科院分区:
医学1区
文献类型:
--
作者:
Compton WM;Valentino RJ;DuPont RL

文献摘要

参考文献

被引文献

相似文献

应对美国阿片类药物危机的干预措施主要针对阿片类药物的使用、滥用和成瘾,但由于阿片类药物危机包括多种物质,干预措施的阿片类药物特异性可能会限制他们解决更广泛的多物质使用问题的能力。阿片类药物与其他物质的重叠范围很广,从在整个生命周期内使用的物质之间的变化,到同时使用跨越相似和不同药理类别的物质。有证据表明,非医用阿片类药物使用者相当普遍地使用其他药物,这种多物质的使用导致发病率和死亡率的增加。将其他物质添加到阿片类药物的原因包括提高高(加性或协同奖励),通过服用一种药物补偿另一种药物的不良影响,补偿消极的内部状态,或与所有物质消耗有关的共同易感。但摄入多种物质本身可能会产生独特的影响。为了实现最大效益,需要在预防和治疗干预、逆转过量用药、公共卫生监测和研究的各个领域解决阿片类药物与多种其他物质重叠的问题。通过解决多种消费模式和人们将阿片类药物与其他物质混合的原因,可以加强干预和研究。
Interventions to address the U.S. opioid crisis primarily target opioid use, misuse, and addiction, but because the opioid crisis includes multiple substances, the opioid specificity of interventions may limit their ability to address the broader problem of polysubstance use. Overlap of opioids with other substances ranges from shifts among the substances used across the lifespan to simultaneous co-use of substances that span similar and disparate pharmacological categories. Evidence suggests that nonmedical opioid users quite commonly use other drugs, and this polysubstance use contributes to increasing morbidity and mortality. Reasons for adding other substances to opioids include enhancement of the high (additive or synergistic reward), compensation for undesired effects of one drug by taking another, compensation for negative internal states, or a common predisposition that is related to all substance consumption. But consumption of multiple substances may itself have unique effects. To achieve the maximum benefit, addressing the overlap of opioids with multiple other substances is needed across the spectrum of prevention and treatment interventions, overdose reversal, public health surveillance, and research. By addressing the multiple patterns of consumption and the reasons that people mix opioids with other substances, interventions and research may be enhanced.
DOI: 10.15585/mmwr.mm6810a6
发表时间: 2019-03-15
影响因子: 33.9
作者:
Cranston, Kevin;Alpren, Charles;Demaria, Alfred, Jr.
通讯作者: Demaria, Alfred, Jr.
CDC规定慢性疼痛的阿片类药物的指南 - 美国,2016年。
DOI: 10.1001/jama.2016.1464
发表时间: 2016-04-19
期刊: JAMA
影响因子: --
作者:
Dowell D;Haegerich TM;Chou R
通讯作者: Chou R
DOI: 10.15585/mmwr.mm6448a3
发表时间: 2015-12-11
影响因子: 33.9
作者:
Des Jarlais, Don C.;Nugent, Ann;Holtzman, Deborah
通讯作者: Holtzman, Deborah
DOI: 10.3109/10826087809039301
发表时间: 1978-01-01
期刊: INTERNATIONAL JOURNAL OF THE ADDICTIONS
影响因子: --
作者:
EGGER, GJ;WEBB, RAJ;REYNOLDS, I
通讯作者: REYNOLDS, I
DOI: 10.1111/add.13516
发表时间: 2016-11-01
期刊: ADDICTION
影响因子: 6
作者:
Darke, Shane
通讯作者: Darke, Shane